Neonatal chronic kidney failure associated to cyclo-oxygenase inhibitors administered during pregnancy;Insufficienza renale cronica neonatale associata ad assunzione di un inibitore della ciclo-ossigenasi-2 durante la gravidanza

Minerva Urologica e Nefrologica

Volumn 53, Issue 2, 2001, Pages 113-116

  Peruzzi, L ^a   Gianoglio, B ^a   Porcellini, G ^a   Conti, G ^a   Amore, A ^a   Coppo, R ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

Chronic infant; Cyclo oxygenase inhibitors; Kidney failure; Newborn; Prostaglandin endoperoxide synthetase

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NIMESULIDE;

ANURIA; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG SAFETY; ENZYME INHIBITION; HUMAN; KIDNEY BIOPSY; NEWBORN; OLIGOHYDRAMNIOS; OLIGURIA; PERITONEAL DIALYSIS; PREGNANCY; TOCOLYSIS;

ADULT; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INFANT, NEWBORN; KIDNEY FAILURE, CHRONIC; PREGNANCY; SULFONAMIDES; TOCOLYTIC AGENTS;

EID: 0034786021     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sawdy R, Slater D, Fisk N, Edmonds DK, Bennet P. Use of a cyclo-oxygenase type-2-selctive non-steroidal antinflammatory agent to prevent preterm delivery. Lancet 1997;350:265-6.
2. Souter D, Harding J, Mc Cowan L, O'Donnel C, McLeay F, Baxendele H. Antenatal indomethacin adverse effects confirmed. Aust NZ J Obstet Gynecol 1998;38:11-6.
3. Komhoff M, Grone HJ, Klein T, Seyherth HW, Nusing RM. Localization of cyclooxygenase -1 and -2 in adult and fetal human kidney. Implication for renal function. Am J Physiol 1997;274:F460-8.
4. Slater DM, Berger LC, Newton R, Moore GE, Bennet PR. Expression of cylooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynecol 1995;172:77-82.
5. Langenbach R, Morham SG, Tiano HF, Loftin CL, Ghanayem BI, Chuleda PC et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92.
6. Morham SG, Langenbach R, Loftin C, Tiano HF, Vouloumanos N, Jennette JC et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-82.
7. Dinchuk JE, Car BD, Fochet RJ, Johnston JJ, Joffree BD, Covington MB et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-9.
8. Komhoff M, Wang JL, Cheng HF et al. COX-2 selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000;57:414-22.
9. Khan KN, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL et al. Interspecies differences in renal localization of cyclo-oxygenase isoforms: implications in nonsteroidal antinflammatory drug-related nephro-toxicity. Toxicol Pathol 1998;26:612-20.
10. Peruzzi L, Gianoglio B, Porcellini MG, Coppo R. Neo-natal end stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-2 selective inhibitor nimesulide as tocolytic. Lancet 1999;354:1615.
11. Traynor T, Schnerman J, Briggs JP. Cyclo-oxygenase-2 inhibition with NS-398 blocks macula densa stimulated renin secretion in the isolated perfused juxtaglomerular apparatus. J Am Soc Nephrol 1998;9:349A.
12. Yerkes E, Nishimura H, Miyazaki Y, Tsuchida S, Brock III JW, Ichikawa I. Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and the human. Kidney Int 1998;54(S 67):S75-7.